A Catalyst Stack on a Crashing Stock: Myriad Bets Everything on the Cancer Care Continuum
One year in, the bet is still ahead of the numbers
It has been exactly one year since Sam Raha took the CEO seat promising focus, and the focus is now a single word: cancer testing. The company has reorganized around the Cancer Care Continuum, added dedicated sales forces, hired over 100 account executives, and is now in the middle of what the new CCO Brian Donnelly describes as
one of the most important launch cycles in the company's history.
Q1 revenue of $200M was up just 2% year over year and inside the guided range, but the bottom line still bleeds: adjusted EBITDA was a $4.5M loss, adjusted EPS −$0.09, and net income −$34M. The stock tells the harsher story — down 88% from its 2018 peak and 49% off its July 2026 high, with the 90-day tape violently breaking a 13-week, +29% rally into a −41% drawdown. Investors are not paying for the narrative yet.
The launch stack: MRD first, everything else in triage
The centerpiece is Precise MRD, which went live in alpha for breast cancer in March. Sam sounded genuinely encouraged by the early operational metrics: “We've been pleased with the yield of our assay and also early numbers for turnaround time for the baseline and monitoring assays, all of which are tracking within our pre-established internal targets, which we believe will allow us to be competitive with other on-market tests.” — Samraat Raha, Chief Executive Officer · 2026-05-05 In a notable acceleration, they pulled forward colorectal cancer and renal commercial testing into Q3.
That haste sits in sharp tension with the prior quarter's sober caveat. On the February call, Sam was explicit about the reimbursement timeline:
So management is deliberately front-running MolDX coverage, spending ahead of a launch that will contribute nothing to this year's top line — a bold, if risky, bet that the community-oncology channel (nearly 3,500 oncologists) gives them a first-mover edge on low-shedding tumors.We are not assuming that we would get coverage until sometime in 2027. So we're assuming really no revenue from MRD in our 2026 numbers.
The second pillar is FirstGene, the combined NIPT + carrier screen that is supposed to revive the struggling prenatal franchise. Brian laid out the differentiation plainly: “The FirstGene screen offers the first and only simultaneous screen of patient carrier status, fetal single gene, fetal chromosome and fetal RHD status, all delivered collectively in a single integrated report.” — Brian Donnelly, Chief Commercial Officer · 2026-05-05 But that business remains the soft spot — Prenatal volumes fell 15% year over year, and Sam admitted the quarter was “a little bit slower than expected” — Samraat Raha, Chief Executive Officer · 2026-05-05, banking on FirstGene plus a dedicated prenatal sales team to return to growth in the second half.
Rebuilding the muscle before the machines arrive
What carries the investment is commercial team expansion and one very profitable engine: GeneSight. Mental health delivered 24% year-over-year revenue growth on 7% volume, with a record 39,000 ordering clinicians. Ben pointed to the durable driver: “the aggregation of these coverage wins has become a meaningful tailwind for the business,” — Ben Wheeler, Chief Financial Officer · 2026-05-05 powered by biomarker law tailwinds. The whole strategy aims at one word — share gain — which has been this company's biggest momentum keyword over the past year.
The numbers: disciplined squeeze meets aggressive investment
There is a real tension between the squeeze and the spend. Gross margin held at 68.7%, roughly flat year over year, and effective SG&A was actually down 6% — the cost discipline is real. But net margin landed at −17%, and the balance sheet is stretched: effective net cash is just $1M (the company cites $199M of capital access, but on a net basis it is essentially zero), while liabilities-to-assets have climbed to 50%. On valuation, price-to-revenue sits at 0.5x — historically cheap, but cheap for a reason.
The bridge is hereditary cancer. In Q1, volumes grew 14% year over year (16% in the unaffected population), and that profit engine is what funds the MRD, FirstGene and Prolaris+AI launches. Ben captured the hope: “It's important to recall that when you look at 2025, Q1 was the softest ASP quarter for GeneSight” — Ben Wheeler, Chief Financial Officer · 2026-05-05 — implying this quarter becomes a higher baseline. Prior quarter commentary reinforces the same patience: last call, the team flagged “the expectation that we'll see a decline in prenatal year-over-year in Q1 with recovery in Q2 and beyond” — Ben Wheeler, Chief Financial Officer · 2026-02-23, and Sam framed the growth levers as a multi-quarter path to “high single-digit to low double-digit sustained profitable growth” — Puneet Souda, Analyst · 2026-02-23 starting in 2027.
Net-net, this is a turnaround story where the thesis is visible but not yet profitable. The catalog of catalysts is packed into the next four quarters, the sales force is being rebuilt from the ground up, and the company is deliberately spending ahead of reimbursement. For a $360M-market-cap name sitting 49% off its high, the market is effectively saying: show me the launch execution before the tape rewards it. This call showed the plan, not the proof.